CXCL13 and myeloid sarcoma: Recent meta-analysis of research data based on over 200 studies with cumulative number of ca. 13,500 MS patients indicated CSF levels of CXCL13 and INF-γ as, respectively, strong and moderate differentiating biomarkers of MS [24], which also finds support in later studies assessing multiple molecular factors in MS [51].